Zacks Research Raises Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Research analysts at Zacks Research boosted their FY2026 EPS estimates for shares of Globus Medical in a research report issued on Friday, May 22nd. Zacks Research analyst Team now expects that the medical device company will earn $4.73 per share for the year, up from their previous forecast of $4.40. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2027 earnings at $1.23 EPS.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same period in the prior year, the business earned $0.68 EPS. The firm’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS.

GMED has been the subject of a number of other reports. Royal Bank Of Canada upped their price objective on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Barclays upped their price objective on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Wells Fargo & Company decreased their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Finally, TD Cowen upgraded Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $106.36.

Globus Medical Price Performance

Shares of NYSE GMED opened at $85.10 on Wednesday. The stock has a market capitalization of $11.55 billion, a P/E ratio of 19.79, a price-to-earnings-growth ratio of 1.75 and a beta of 1.00. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40. The business has a fifty day moving average price of $87.27 and a 200 day moving average price of $88.32.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC increased its holdings in shares of Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares during the period. Invesco Ltd. increased its holdings in shares of Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after purchasing an additional 3,595,339 shares during the period. Bank of Montreal Can boosted its stake in shares of Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after buying an additional 3,351,380 shares during the last quarter. Sculptor Capital LP boosted its stake in shares of Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after buying an additional 58,000 shares during the last quarter. Finally, William Blair Investment Management LLC boosted its stake in shares of Globus Medical by 17.2% in the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after buying an additional 414,134 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.